Upgrade to SI Premium - Free Trial

Sarepta Therapeutics (SRPT) PT Lowered to $50 at BMO Capital Following Mangement Call

July 18, 2025 12:04 PM
BMO Capital analyst Kostas Biliouris lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $50.00 (from $70.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles